Ocular Therapeutix (OCUL) Receivables - Other (2013 - 2017)
Ocular Therapeutix's quarterly Receivables - Other came in at $688000.0 in Q1 2017, up 68700.0% quarter-over-quarter from $1000.0 in Q3 2014.
Ocular Therapeutix has reported Receivables - Other for 3 years, with the latest figure at $688000.0 in Q1 2017.
- For the quarter ending Q1 2017, Receivables - Other changed N/A year-over-year to $688000.0; the trailing twelve-month figure through Mar 2017 stood at $688000.0 (changed N/A YoY), and the FY2013 full-year result was $19000.0, changed N/A from the prior year.
- Receivables - Other for Q1 2017 stood at $688000.0, up from $1000.0 in the prior quarter.
- The five-year high for Receivables - Other was $688000.0 in Q1 2017, with the low at $1000.0 in Q2 2014.
- Average Receivables - Other over 3 years is $177250.0, with a median of $10000.0 recorded in 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 688,000.00 |
| Mar 31, 2017 | 688,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Dec 31, 2013 | 19,000.00 |
| Dec 31, 2013 | 19,000.00 |